The two leading GLP-1 pills finally went head-to-head, and the results published in The Lancet this week are decisive: Eli Lilly's orforglipron beat oral semaglutide on both blood sugar and weight loss in a 52-week trial of 1,698 adults with type 2 diabetes. The catch is tolerability — orforglipron's gastrointestinal side effects and dropout rate ran roughly double.
Research-context information only. This article reports trial data and what it means for buyers. It is not medical advice. Talk to a licensed physician before starting any GLP-1 protocol. Retatrutide, mentioned below, is an investigational drug not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction.
For anyone weighing an oral GLP-1, this is the first clean apples-to-apples comparison — but it also sidesteps the question most of our readers actually ask: which of these can you get, and for how much.
What ACHIEVE-3 Found
ACHIEVE-3 was the first head-to-head Phase 3 trial pitting two oral GLP-1 receptor agonists against each other. Researchers randomized 1,698 adults with type 2 diabetes — inadequately controlled on metformin, starting HbA1c around 8.3% — to one of four arms: orforglipron at 12 mg or 36 mg, or oral semaglutide at 7 mg or 14 mg, once daily for 52 weeks.
On the primary endpoint, HbA1c reduction, orforglipron won at both doses:
| Drug (daily dose) | HbA1c reduction | Weight loss | Weight loss (lbs) |
|---|---|---|---|
| Oral semaglutide 7 mg | -1.1% | -3.7% | -7.9 lbs |
| Oral semaglutide 14 mg | -1.4% | -5.3% | -11.0 lbs |
| Orforglipron 12 mg | -1.9% | -6.7% | -14.6 lbs |
| Orforglipron 36 mg | -2.2% | -9.2% | -19.7 lbs |
The pattern is consistent: even the low orforglipron dose (12 mg) out-lowered the high oral semaglutide dose (14 mg) on both blood sugar and weight. At the top doses, orforglipron nearly doubled the weight loss — 9.2% versus 5.3%.
Lead investigator Dr. Julio Rosenstock called it "the first head-to-head comparison between two oral GLP-1 receptor agonist therapies in adults with type 2 diabetes, and the differences were clinically meaningful."
The trade-off showed up in tolerability. The dominant side effects were the usual GLP-1 complaints — nausea, diarrhea, vomiting, dyspepsia, and decreased appetite — but they hit harder on orforglipron. Treatment discontinuation from adverse events ran 8.7% (12 mg) and 9.7% (36 mg) for orforglipron, versus 4.5% and 4.9% for oral semaglutide. In plain terms: better numbers, more nausea, roughly twice the dropout.
What This Means for You
Here's the part the headlines miss. This was a diabetes trial, so the weight-loss numbers look modest for both drugs — type 2 diabetes patients lose less than non-diabetic obesity patients on every GLP-1. In dedicated obesity trials, orforglipron runs closer to 12-13% and injectable semaglutide closer to 15%. ACHIEVE-3 is about which pill controls blood sugar better; it's not the ceiling for weight loss.
More important for most readers: the winner of this trial is the harder one to get. Orforglipron (Foundayo) is prescription-only, approved April 2026, running about $149/month self-pay — with insurance copays as low as $25 and Medicare Part D access from July 1, 2026. It's a genuine convenience win: a daily pill, no needles, no refrigeration, no reconstitution.
But if the goal is maximum weight loss for the lowest cost, the pill format isn't where the strongest data lives. Oral semaglutide — the loser of this trial — exists because swallowing a peptide is hard: only about 1% of an oral semaglutide dose is absorbed. The injectable version of the same molecule delivers roughly 15% weight loss, three times the oral pill's ~5% in these diabetes patients. Injectable GLP-1s remain the access route most of our readers use:
- Best Semaglutide Vendors — current pricing on 5mg and 10mg vials, with COA status
- Best Tirzepatide Vendors — the dual agonist that beats semaglutide on weight, pricing on 10mg/30mg/60mg vials
- All Active Vendor Coupons — current discount codes across recommended vendors
The honest framing: orforglipron is the best oral GLP-1 for blood sugar, and if a prescription pill fits your life and budget, ACHIEVE-3 says it's the stronger of the two. But the decision most people face isn't "which pill" — it's "pill versus injection," and on raw potency the injectables still win.
